On December 17, 2013, Depomed, Inc. (NASDAQ:DEPO) announced it had acquired the U.S. rights to CAMBIA (diclofenac potassium for oral solution) from Nautilus Neurosciences for $48.7 million in cash. CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). The company held a conference call after the close of the market on the 17th to discuss the details of the product acquisition with investors. We view the transaction as yet another fine deal for Depomed, a company with significant cash and a growing special pharmaceutical business focused on pain and neurology. Below we discuss the details of the transaction, provide some...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|